Vascular endothelial growth factor (VEGF) represents a major target for therapeutic interventions in metastatic renal cell carcinoma. In this randomized phase II study we evaluated the safety and efficacy of the VEGF blocker AVE0005 (VEGF Trap), or aflibercept, in previously treated renal cell carcinoma patients. Aflibercept at a dose of 4 mg was safe and had favorable clinical activity. These results provide the rationale for further investigation of aflibercept in rational combination strategies for renal cell carcinoma patients. Background: Aflibercept is a recombinantly produced fusion protein that has potent anti-vascular endothelial growth factor (VEGF) activity. We tested whether aflibercept has clinical activity in clear-cell renal cell carcinoma (ccRCC). The recommended phase II dose was 4 mg/kg but several patients (pts) treated at 1 mg/kg showed prolonged progression-free survival. We therefore tested both doses in a parallel group randomized trial. Patients and Methods: Eligible pts had histologically confirmed advanced or metastatic ccRCC and previous treatments included exposure to a VEGF receptor tyrosine kinase inhibitor. Pts received aflibercept (either 1 mg/kg or 4 mg/kg) on day 1 of a 14-day cycle until disease progression. Pts randomized to 1 mg/kg could crossover to 4 mg/kg at the time of disease progression. The primary end point was proportion alive and progression-free at 8 weeks. A Simon 2-stage design was used for each arm with 33 and 24 eligible pts per arm enrolled in stages 1 and 2. Results: Ninety-four pts were enrolled, 59 and 35 to 4 mg and 1 mg doses, respectively. Seventy-two percent had 1 previous treatment most commonly sunitinib. Sixteen eligible pts crossed over at the time of disease progression to the 4-mg dose. Most common adverse events were hypertension, proteinuria, and fatigue. Only 4 pts reported Grade 4 or higher toxicity. With 36 of 59 pts (61%) progression-free at 8 weeks, the 4-mg/kg dose met protocol-specified efficacy criteria. Conclusion: Aflibercept is active in previously treated ccRCC and might be worthy of further study.
Introduction
Renal cell carcinoma is the fourth most common genitourinary cancer with approximately 30,000 new cases diagnosed annually causing 12,000 deaths. 1 Approximately 45% of patients, at the time of diagnosis, have disease localized to their kidney; 30% have distant metastases; and 25% have locally advanced disease. 2 Surgical resection is the only potentially curative therapy. The 5-year survival for stage I or II disease patients is 66%; 42% for stage III disease; and < 5% for stage IV disease. 2 Angiogenesis, an orderly and tightly controlled process through which a tumor is neovascularized, is required for metastasis and tumor progression. This process is controlled by multiple factors, one of which is the vascular endothelial growth factor (VEGF)-a protein that has a critical role in initiating and sustaining tumor angiogenesis. Clear-cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, harbors genetic and epigenetic alteration of the von Hippel-Lindau gene and consequently the stabilization of the transcriptional factor hypoxia-inducible factor (HIF) with downstream upregulation of VEGF. 2 Over the past 10 years the use of VEGF/ VEGF receptor targeting drugs has changed the treatment of ccRCC. However, despite the proven clinical benefit, eventually patients develop progressive disease because of drug resistance. Aflibercept has been developed as a decoy receptor and blocking drug with greater binding affinity to VEGF compared with bevacizumab. 3 Its ability also to bind other related proangiogenic factors such as VEGF-B and the placental growth factors, PlGF1 and 2 makes this agent an appealing antiangiogenesis drug for ccRCC. Aflibercept has been reported to have preclinical activity in several tumor models including renal-cell carcinoma and has been approved for the treatment of colon carcinoma in combination with chemotherapy. [4] [5] [6] In the present study we evaluated the efficacy and safety of 2 doses of aflibercept in the treatment of patients with metastatic ccRCC who had progressive disease after tyrosine kinase inhibitor (TKI) therapy.
Patients and Methods

Study Design and Participants
Eligible patients were 18 years of age or older with histologically confirmed metastatic or unresectable ccRCC with measurable lesions per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Patients also had evidence of progressive disease after a previous VEGF receptor TKI treatment received for at least 12 weeks; an Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2; adequate organ function measured according to appropriate blood chemistries; and recovered from any toxic effects of previous radiotherapy or surgical procedures within 4 weeks before randomization. No previous cellular therapy, vaccine, hormonal, or chemotherapy was allowed. HIV-positive patients receiving anti-retroviral therapy were also excluded because of pharmacokinetic interactions with aflibercept; patients with history of metastatic central nervous system, pulmonary embolism, deep venous thromboembolism, or other thromboembolic events were excluded.
Patients were randomized into 2 treatment arms (A and B) to determine the effect of 2 different doses of aflibercept. Randomization was stratified according to Memorial Sloan Kettering Cancer Center 7 risk category and previous cytokine therapy. Patients randomized to arm A received 4 mg/kg of aflibercept, on day 1 of every 14-day cycle, intravenously over 1 hour into a peripheral vein or central venous catheter using an infusion pump. Patients in arm B received 1 mg/kg using the same schedule and infusion method (Figure 1 ). Tumor status was assessed every 8 weeks (every 4 cycles) after starting treatment. Tumor progression was defined using RECIST criteria. At the time of progression, the dose of patients in arm B was escalated to Clinical Genitourinary Cancer December 2017 -643 4 mg/kg. A patient continued receiving protocol treatment until he or she developed progressive disease or unacceptable toxicity and all patients, including those who discontinued protocol therapy early, were followed for response until disease progression and for survival for 3 years from the date of randomization.
Statistical Analysis
The primary end point was defined as the proportion of patients alive and progression-free at 8 weeks. Progression-free survival (PFS) was defined as time from randomization to the earlier of documentation of disease progression or death. Patients alive and progression-free at the time of analysis were to be censored at the date of last disease assessment without evidence of disease progression. Extensive data on PFS among patients who had previously been treated with TKIs were not available at the time the study was designed. In this study, a progression-free proportion of 50% at 8 weeks was not of interest, whereas a proportion at 8 weeks of 67% signified that aflibercept was worthy of further study. Assuming an exponential distribution, this corresponds to an improvement in median PFS from 8 weeks to 14 weeks.
A 2-stage design was used within each arm. In the first stage, 33 eligible patients were accrued. If 16 or fewer patients were progression-free at 8 weeks, then the arm was to be closed. If at least 17 patients were progression-free at 8 weeks, then an additional 24 eligible patients would be accrued. If at least 34 of 57 eligible patients were progression-free at 8 weeks, the dose would be considered worthy of further study. Using this design, the probability on each arm of declaring a dose unworthy of further study was 91% (statistical power) if the true 8-week progression free rate was 50% and 10% (type I error) if the true 8-week progression-free rate was 67%. To assure 33 and 24 eligible patients in the 2 stages of accrual, 35 and 25 patients, respectively, were to be randomized per stage and dose level for a total maximum of 60 patients per treatment arm.
Secondary end points were objective response rate, toxicity, response duration, and overall survival. A true objective response rate of 10% was of interest, whereas a true rate of 1% was not. With 57 eligible patients per arm, the response rate would be considered interesting if 3 or more patients achieved an objective response. All patients receiving treatment, regardless of eligibility, were included in the assessment of toxicity. This study used Common Terminology Criteria for Adverse Events (CTCAE) version 3 definition and only events with CTCAE attribution of possibly, probably, or definitely are reported. Response duration was defined as the time, in weeks, from onset of treatment response to disease progression. Patients without documented progression were censored at the date of last follow-up.
The efficacy analysis population included all eligible and treated patients. All treated patients, regardless of eligibility, were included in the toxicity analysis. The KaplaneMeier (KM) method 8 was used to describe overall and PFS. Descriptive statistics were used to summarize patient characteristics at baseline. Two-sided 90% exact binomial confidence intervals (CIs) were computed for the assessment of toxicity and response rate.
Results
The total patient accrual was 94. The study was activated on December 21, 2007 and suspended on March 27, 2012 having reached its stage 1 accrual goal. The study was then reactivated on June 20, 2012 and only arm A reopened to accrual-arm B remained suspended and subsequently closed for failing to meet protocolspecified efficacy criteria for continuation to stage 2. A total of 35 patients were accrued to arm B by the end of stage 1; 3 of these 35 patients were ineligible for efficacy analysis of PFS. The number of patients alive and progression-free at 8 weeks was 16 (50%) and thus arm B did not meet the criteria for continuing to stage 2 accrual. Fiftynine patients were accrued to arm A by the end of stage 2 and the study was terminated on December 6, 2013. Table 1 shows demographic and prognostic characteristics of patients in both treatment arms. The median age was 60 and 62 years,
The randomization process was effective in ensuring that patients in the treatment arms were comparable with respect to demographic and prognostic factors using appropriate statistical tests.
Toxicity Table 2 provides a summary of treatment-related toxicities of all Grades. The denominator included patients who received protocol therapy irrespective of eligibility status. The most common treatment-related toxicities in arm A were fatigue (63%), hypertension (54%), proteinuria (47%), and anorexia (39%). The proportion (90% CI) of severe (Grade 3 or higher) toxicity in arms A and B was 61.4% (49.7-72.2) and 52.9% (37.7-67.8), respectively. One patient in treatment arm B experienced a Grade 5 event described as intracranial hemorrhage. There were 10 Grade 5 events (6 in treatment arm A and 4 in arm B) but were considered unrelated to treatment-6 were due to disease progression and 4 each due to renal failure, dyspnea, infection, and upper respiratory tract-related toxicity.
Efficacy
As estimated from KM survival estimates, the proportion of patients alive and progression-free at 8 weeks (90% CI) was 70% (59%-79%) in treatment arm A and 52% (37%-66%) in arm B. The proportion alive and progression-free estimate of 70% for arm A was higher than the proportion of interest value of 67% specified in the protocol. Likewise, the number of patients alive and progressionfree at 8 weeks was 39, which was higher than the protocol prespecified number of 34 patients suggesting worthiness for further study. The PFS curve is shown in Figure 3 . The estimated median PFS for treatment arm A and B patients were 10.86 and 8.29 weeks, respectively. The P value of the log rank test in a comparison of PFS between arms was .37; however, this study was not powered to detect difference in PFS. A total of 52 (91%) events occurred among patients in treatment arm A and 31 (97%) in treatment arm B. Table 3 shows overall response according to treatment arm among patients who were eligible and treated. The response rates with a 90% CI for arm A and B were 5.3% (1.4-13.0) and 3.1% (0.2-14.0), respectively. The prespecified number of objective responses of interest (! 3 patients) was satisfied in arm A, suggesting efficacy. Waterfall plots of maximum percent change from baseline in the sum of lesions longest diameter for both treatment arms are shown in Figure 4 . A reference line at À30% represents the RECIST criteria cutoff corresponding to a partial response to treatment. A patient in arm B was identified as having progressive disease despite having approximately a 70% reduction in lesion size because the patient developed multiple new lesions. Four patients, from both treatment arms, experienced an objective response, the KM estimated median response duration (90% CI) among these 4 patients was 43.9 (31.4-56.4) weeks. The median response duration (90% CI) among patients (n ¼ 23) with stable disease was 13.0 (8.1-22.6) weeks. Sixteen patients in treatment arm B (1 mg/kg) had their dosage escalated to 4 mg/kg after disease progression. The median PFS (90% CI) before and after escalation were 8.6 (8.0-14.0) weeks and 14.6 (7.6-33.0) weeks, respectively ( Figure 5 ). An overall 
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Discussion
The results from this study confirm the hypothesis that continuous VEGF blockade after disease progression using VEGF receptor tyrosine kinase inhibitors might have clinical benefit in ccRCC patients. This study met the protocol-specified criteria for significant improvement in PFS among arm A patients only (PFS of ! 0.67 and ! 34 patients alive and progression-free at 8 weeks). Also, the protocol-specified criterion for objective response was met among arm A patients only (! 3 patients with response). Overall, the treatment was well tolerated, although there was a greater percentage of patients who experienced treatment-related, Grade 3 or higher, toxicities in arm A compared with patients in arm B.
The treatment landscape for ccRCC is rapidly evolving. 9 The recent approval of 2 new multikinase inhibitors in the second-line setting such as cabozantinib and lenvatinib suggests that sequential inhibition of additional tyrosine kinases besides VEGF receptor tyrosine kinase might induce clinical benefit. 10, 11 The treatment options for ccRCC are also significantly expanding because of the Food and Drug Administration (FDA) approval and clinical development of receptor programmed cell death-1/programmed cell death ligand 1 (PD1/PD-L1) inhibitors. 12 Continuous VEGF inhibition remains an important tool to induce prolonged clinical response in ccRCC patients. The original FDA approval of axitinib has validated retrospective studies suggesting that sequencing of 
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TKIs can still induce disease control despite disease progression after first-line therapies with anti-VEGF therapies. 13 The VEGF ligand blocker bevacizumab has been approved in combination with interferon a for the treatment of renal cell carcinoma in the first-line setting on the basis of the results of 2 phase III randomized studies. 14, 15 Different combination strategies with bevacizumab have also been tested but these have been hampered by toxicities, and did not show greater efficacy compared with single-agent bevacizumab. 16 The assessment of the role of bevacizumab in the second-and third-line setting in renal-cell carcinoma patients has been relatively limited. One report showed an objective response rate of 9% and a median PFS of 4.4 months in previously treated ccRCC patients. 17 In our study, the median PFS, objective response rate, and toxicity profile observed in patients randomized to either the 4-mg aflibercept arm or in those who crossed over to that dose 
Roberto Pili et al
Clinical Genitourinary Cancer December 2017 -647 appear similar to the historical data attributed to bevacizumab in the same setting. Thus, the results from our clinical trial are consistent with a dose-dependent benefit of aflibercept that was evident also in the crossed-over patients. A similar dose-dependent effect was observed also in the original single-agent study with bevacizumab in renal-cell carcinoma. 18 As the armamentarium for treating ccRCC is growing it becomes challenging to position new drugs in the current treatment algorithm. Aflibercept has shown preclinical more potent and broader activity than bevacizumab. 4 Identifying patients who might most benefit from the pharmacodynamics of aflibercept might represent a clinically relevant question. As HIF-2a antagonists are becoming available, a potential combination with an effective VEGF blocker such as aflibercept appears to be a rational strategy for ccRCC.
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Conclusion
This study confirms the potential benefit of VEGF blockade in previously treated patients with metastatic ccRCC. Aflibercept showed evidence of activity in previously treated ccRCC and might be worthy of further study in rational combination strategies in which continuous VEGF blockade might be beneficial.
Clinical Practice Points
The treatment of metastatic ccRCC is rapidly evolving but therapies targeting the VEGF axis remain the main treatment of this disease.
The use of the VEGF blocker aflibercept in pretreated ccRCC patients was safe and showed clinical benefit. Rational combination strategies with aflibercept might be beneficial in ccRCC patients.
